{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/dyspepsia-proven-gord/management/dyspepsia-proven-gord/","result":{"pageContext":{"chapter":{"id":"6898f6b1-0345-5601-a084-c0f92474d0c9","slug":"dyspepsia-proven-gord","fullItemName":"Scenario: Dyspepsia - proven GORD","depth":2,"htmlHeader":"<!-- begin field 17b4ea64-c011-4f3e-b047-797f1df018f8 --><h2>Scenario: Dyspepsia - proven GORD</h2><!-- end field 17b4ea64-c011-4f3e-b047-797f1df018f8 -->","summary":"Covers the management of adults with endoscopically-determined gastro-oesophageal reflux disease (GORD) in primary care.","htmlStringContent":"<!-- begin item 751b75b7-1302-475b-8d57-88bd285f7b7d --><!-- begin field 65ff99d8-1ad4-450e-8319-acbd0084c38f --><p>From age 18 years onwards.</p><!-- end field 65ff99d8-1ad4-450e-8319-acbd0084c38f --><!-- end item 751b75b7-1302-475b-8d57-88bd285f7b7d -->","topic":{"id":"83831d3c-e98d-5e82-9fb9-cbd189e834d5","topicId":"8116d56b-de40-4191-af22-5152cc8f533c","topicName":"Dyspepsia - proven GORD","slug":"dyspepsia-proven-gord","lastRevised":"Last revised in April 2017","chapters":[{"id":"2b894900-36e2-56c8-9d00-aea95f9acd57","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"491fd89e-ec21-5541-b37c-3579bd40472f","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"6d91073e-8bb8-57e8-8ebf-c1b2832b3377","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"69955f21-cf75-5568-9c39-b6894659d140","slug":"changes","fullItemName":"Changes"},{"id":"69e41821-9e9f-506e-bf29-9bb662d19fc5","slug":"update","fullItemName":"Update"}]},{"id":"a5332092-2e76-52c3-9c78-c55c73be1c36","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"ac987149-bd5e-543a-8025-d0a50c72b165","slug":"goals","fullItemName":"Goals"},{"id":"c282f1cd-c0cd-5cc2-b030-047fa174fc2b","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"35e91b3d-56f5-5130-8d0e-f0ad612196a3","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"fac73702-952e-57cf-a136-d52c4400cf78","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"8add7bfe-1e06-5768-958d-3c09d529c285","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"bb66df20-4142-59d4-913e-cf945ca4dacc","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"d0449fde-d38f-58a1-aee2-098d0ab6ff60","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"0a206efc-7aca-58e6-8462-5278f905b372","slug":"definition","fullItemName":"Definition"},{"id":"ce8c37c8-0936-52a2-87a7-0cbf130e1ce3","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"e1423a90-52a5-592c-ba4d-7f5a420ac54a","slug":"prevalence","fullItemName":"Prevalence"},{"id":"cac2f410-0ab9-55d6-8bb8-acbe7735bd9c","slug":"complications","fullItemName":"Complications"},{"id":"9047f011-fcc3-521a-a802-30ac67c85c10","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"a4a2f3e7-53b3-50ce-b717-6a6e8e5a219d","fullItemName":"Management","slug":"management","subChapters":[{"id":"6898f6b1-0345-5601-a084-c0f92474d0c9","slug":"dyspepsia-proven-gord","fullItemName":"Scenario: Dyspepsia - proven GORD"}]},{"id":"adea4c6d-b925-5d85-92be-9d322d882faf","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"bda71033-db69-5e58-977e-9d415fe4f646","slug":"proton-pump-inhibitors","fullItemName":"Proton pump inhibitors"},{"id":"15ddfd64-70ae-5a0e-b1ca-6b8811278010","slug":"h2-receptor-antagonists","fullItemName":"H2-receptor antagonists"}]},{"id":"dc717df5-19a4-5e7d-8391-be3e281ebdc8","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"70508c23-67ec-5f56-b6cd-a9612c7e4e9f","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"713a3147-c4ed-5200-a0ab-51e195929400","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"a10b2f69-154b-5dcc-8599-ae8de77e7eda","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"6155a413-aefc-5575-b07c-111ad7697022","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"f73cf98a-26ab-5f78-b8e4-d24d5a849283","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"94379789-e6c4-55fa-b460-965e551f4ea7","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"64699d48-46e4-5ff1-97c0-8e280c75065c","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"a4a2f3e7-53b3-50ce-b717-6a6e8e5a219d","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"4ea4f69c-4dfe-5e70-84f9-6f3542f7dec3","slug":"initial-management","fullItemName":"Initial management","depth":3,"htmlHeader":"<!-- begin field 5de9f52e-8cfa-4c59-b451-df209b1518da --><h3>How should I initially manage a person with proven GORD?</h3><!-- end field 5de9f52e-8cfa-4c59-b451-df209b1518da -->","summary":null,"htmlStringContent":"<!-- begin item 0897e4fc-73ec-40fd-a21b-e9e2cc4dabbc --><!-- begin field 253e1613-bd3f-493a-b67d-ee0aa3d1460b --><ul><li><strong>Assess for any alarm symptoms</strong> that may suggest a <a class=\"topic-reference internal-reference\" href=\"/topics/dyspepsia-proven-gord/background-information/complications/\">complication</a> or other serious underlying pathology, and manage appropriately. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/gastrointestinal-tract-upper-cancers-recognition-referral/\">Gastrointestinal tract (upper) cancers - recognition and referral</a> for more information.</li><li><strong>Offer written information and advice</strong> on the symptoms, self-care, and management options for gastro-oesophageal reflux disease (GORD), such as the NHS patient information leaflet <a data-hyperlink-id=\"bfdeb74d-caec-47d7-84ef-a993008b42fe\" href=\"https://www.nhs.uk/conditions/heartburn-and-acid-reflux/\" target=\"_blank\">Heartburn and gastro-oesophageal reflux disease (GORD)</a>.</li><li><strong>Offer advice on lifestyle measures that may improve symptoms.</strong> Encourage the person to:<ul><li>Lose weight if they are overweight or obese. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/obesity/\">Obesity</a> for more information.</li><li>Avoid any trigger foods, such as coffee, chocolate, tomatoes, fatty or spicy foods.</li><li>Eat smaller meals and eat their evening meal 3–4 hours before going to bed, if possible.</li><li>Stop smoking, if appropriate. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/smoking-cessation/\">Smoking cessation</a> for more information.</li><li>Reduce alcohol consumption to recommended limits, if appropriate. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/alcohol-problem-drinking/\">Alcohol - problem drinking</a> for more information. </li></ul></li><li><strong>Sleep with the head of the bed raised</strong> (for example by placing wood or bricks under the bed head to raise it by 10–20 cm, if practical).<ul><li>Advise people <em>not</em> to use additional pillows, as this may increase intra-abdominal pressure and worsen symptoms.</li></ul></li><li><strong>Assess for stress and anxiety</strong> which may worsen symptoms, and encourage relaxation strategies if needed. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/generalized-anxiety-disorder/\">Generalized anxiety disorder</a> for more information.</li><li><strong>Ask about any over-the-counter medication</strong> such as antacids and/or alginates that have been tried for symptom relief.</li><li><strong>Review the person's medication,</strong> and consider reducing or stopping (if possible and appropriate) any drugs that may cause or exacerbate symptoms, such as:<ul><li>Alpha-blockers, anticholinergics, benzodiazepines, beta-blockers, bisphosphonates, calcium-channel blockers, corticosteroids, nitrates, theophyllines, and tricyclic antidepressants.</li></ul></li><li><strong>If the person has proven GORD:</strong><ul><li>Offer a full-dose proton pump inhibitor (PPI) for 4 weeks to aid healing.</li><li>See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/dyspepsia-proven-gord/prescribing-information/proton-pump-inhibitors/\">Proton pump inhibitors</a> in <a class=\"topic-reference internal-reference\" href=\"/topics/dyspepsia-proven-gord/prescribing-information/\">Prescribing information</a> for more information.</li></ul></li><li><strong>If the person has proven severe oesophagitis:</strong><ul><li>Offer a full-dose PPI for 8 weeks to aid healing.</li><li>Offer a full-dose PPI long-term as maintenance treatment.</li><li>See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/dyspepsia-proven-gord/prescribing-information/proton-pump-inhibitors/\">Proton pump inhibitors</a> in <a class=\"topic-reference internal-reference\" href=\"/topics/dyspepsia-proven-gord/prescribing-information/\">Prescribing information</a> for more information.</li></ul></li><li><strong>Do not arrange testing for <em>Helicobacter pylori</em> infection.</strong></li><li><strong>Advise the person to arrange a follow-up appointment </strong>if there are <a class=\"topic-reference internal-reference\" href=\"/topics/dyspepsia-proven-gord/management/dyspepsia-proven-gord/#refractory-or-recurrent-symptoms\">refractory or recurrent&nbsp;symptoms</a> following initial management.</li></ul><!-- end field 253e1613-bd3f-493a-b67d-ee0aa3d1460b --><!-- end item 0897e4fc-73ec-40fd-a21b-e9e2cc4dabbc -->","subChapters":[{"id":"9148ea1d-5406-59a3-a032-ff419487b6c5","slug":"basis-for-recommendation-580","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field ef6ee309-55b0-48d2-9253-b6551a0a052f --><h4>Basis for recommendation</h4><!-- end field ef6ee309-55b0-48d2-9253-b6551a0a052f -->","summary":null,"htmlStringContent":"<!-- begin item 58003140-8d76-4644-9b60-35bf65c4f4d6 --><!-- begin field 63508375-7f4c-493f-b1b8-d1c8440d4e13 --><p>The recommendations on the initial management of gastro-oesophageal reflux disease (GORD) are largely based on the National Institute for Health and Care Excellence (NICE) clinical guideline <em>Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-gord/references/\">NICE, 2014</a>], expert opinion in the World Gastroenterology Organisation (WGO) guideline <em>Global Perspective on Gastroesophageal Reflux Disease</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-gord/references/\">World Gastroenterology Organisation, 2015</a>], expert opinion in US <em>Guidelines for the diagnosis and management of gastroesophageal reflux disease</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-gord/references/\">Katz et al, 2013</a>], a Cochrane systematic review of short-term treatment of GORD symptoms and endoscopy-negative reflux disease [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-gord/references/\">Sigterman, 2013</a>], and expert opinion in review articles on GORD [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-gord/references/\">Bredenoord, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-gord/references/\">Anderson, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-gord/references/\">Kang, 2015</a>].</p><h5>Assessing for any alarm symptoms</h5><ul><li>The recommendation on assessing for alarm symptoms and managing appropriately is based on the NICE clinical guideline <em>Suspected cancer: recognition and referral</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-gord/references/\">NICE, 2015</a>].</li></ul><h5>Advice on lifestyle modification</h5><ul><li>The NICE clinical guideline states that there is limited or inconclusive evidence from small trials on the benefits of lifestyle modification to reduce GORD symptoms, however expert opinion from the Guideline Development Group recommended these measures as they encourage self-management of GORD and may have more general health benefits [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-gord/references/\">NICE, 2014</a>].<ul><li>Obesity, smoking, and certain trigger foods such as coffee, chocolate, and alcohol may transiently reduce the lower oesophageal sphincter (LOS) tone, and fatty foods delay gastric emptying, however any effect is likely to be small or non-existent [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-gord/references/\">NICE, 2014</a>]. Smoking increases gastric acid production and delays gastric emptying [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-gord/references/\">NICE, 2014</a>].</li><li>The World Gastroenterology Organisation (WGO) states that the role of coffee, alcohol, and smoking in the development of GORD is unclear [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-gord/references/\">World Gastroenterology Organisation, 2015</a>].</li><li>A systematic review of the effect of lifestyle measures on GORD symptoms found limited evidence for the role of avoiding alcohol, caffeine, chocolate, fatty and spicy foods. It found, however, good evidence that weight reduction and smoking cessation are beneficial [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-gord/references/\">Kang, 2015</a>].</li></ul></li></ul><h5>Advice on raising the head of the bed</h5><ul><li>Lying flat may increase reflux episodes as gravity is not preventing acid regurgitation. There is limited evidence from small studies that raising the bed head decreases distal oesophageal acid exposure [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-gord/references/\">NICE, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-gord/references/\">Kang, 2015</a>], and this may be particularly helpful in people who have nocturnal symptoms [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-gord/references/\">Bredenoord, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-gord/references/\">Katz et al, 2013</a>].</li></ul><h5>Managing associated stress and anxiety</h5><ul><li>The recommendation on assessing for and managing associated stress and anxiety is extrapolated from the NICE recommendation to offer psychological treatments to people with functional (non-ulcer) dyspepsia, as this may reduce symptoms in the short-term [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-gord/references/\">NICE, 2014</a>]. This is also supported by expert opinion in a review article on dyspepsia [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-gord/references/\">Ford, 2013</a>].</li></ul><h5>Reviewing the person's medication</h5><ul><li>The recommendation on considering reducing or stopping a variety of drugs that may reduce LOS pressure and cause or exacerbate GORD symptoms is based on expert opinion in the NICE and WGO clinical guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-gord/references/\">NICE, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-gord/references/\">World Gastroenterology Organisation, 2015</a>].</li></ul><h5>Offering initial proton pump inhibitor (PPI) therapy</h5><ul><li>The NICE clinical guideline recommends a full-dose PPI for one month as first-line treatment for endoscopically-proven oesophagitis and endoscopy-negative reflux disease, based on evidence from systematic reviews which showed that [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-gord/references/\">NICE, 2014</a>]:<ul><li>PPIs are signficantly more effective than placebo or histamine (H<sub>2</sub>)-receptor antagonists (H<sub>2</sub>RAs) at healing oesophagitis.</li><li>PPIs appear more effective than H<sub>2</sub>RAs at improving symptoms of endoscopy-negative reflux disease.</li></ul></li><li>NICE also found very low-quality evidence from a network meta-analysis that PPIs were superior to H<sub>2</sub>RAs and placebo in endoscopic healing of severe oesophagitis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-gord/references/\">NICE, 2014</a>].<ul><li>It was not possible to determine which was the best PPI or dose, as it found no evidence that any PPI was more effective than another when compared at equivalent doses.</li></ul></li><li>This is supported by a Cochrane systematic review of evidence from 34 randomized controlled trials (RCTs) of short-term treatment of people with GORD symptoms (not confirmed on endoscopy) or with known endoscopy-negative reflux disease (total n = 1314). In a direct comparison, PPIs were more effective than H<sub>2</sub>RAs and prokinetics [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-gord/references/\">Sigterman, 2013</a>].</li><li>A NICE cost-utility analysis model found that 8 weeks of PPI treatment is more cost-effective than a 4-week regimen for healing of acute severe oesophagitis, regardless of the drug and dose used [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-gord/references/\">NICE, 2014</a>].</li></ul><h5>No need for investigation for <em>Helicobacter pylori</em> (<em>H. pylori</em>) infection</h5><ul><li>The NICE clinical guideline found no evidence for <em>H. pylori </em>investigation in people with GORD [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-gord/references/\">NICE, 2014</a>], and the WGO guideline states that <em>H. pylori</em> status has no effect on symptom severity, recurrence, or treatment efficacy in most people with GORD symptoms [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-gord/references/\">World Gastroenterology Organisation, 2015</a>]. This is supported by expert opinion in a US guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-gord/references/\">Katz et al, 2013</a>] and review articles on GORD [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-gord/references/\">Bredenoord, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-gord/references/\">Anderson, 2015</a>].</li></ul><h5>Arranging follow-up if refractory or recurrent symptoms</h5><ul><li>This recommendation is based on the NICE clinical guideline, as up to 80% of people successfully treated for GORD symptoms will experience a relapse within 1 year [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-gord/references/\">NICE, 2014</a>]. It is also pragmatic, based on what CKS considers to be good clinical practice.</li></ul><!-- end field 63508375-7f4c-493f-b1b8-d1c8440d4e13 --><!-- end item 58003140-8d76-4644-9b60-35bf65c4f4d6 -->","subChapters":[]}]},{"id":"798f4abc-7229-50f4-8f49-47febc6e95d7","slug":"refractory-or-recurrent-symptoms","fullItemName":"Refractory or recurrent symptoms","depth":3,"htmlHeader":"<!-- begin field 35ef68f3-43b1-4770-a7b0-9804c146754e --><h3>How should I manage refractory or recurrent GORD symptoms?</h3><!-- end field 35ef68f3-43b1-4770-a7b0-9804c146754e -->","summary":null,"htmlStringContent":"<!-- begin item 4fc716bf-f9f8-4814-8227-cc0a3574baec --><!-- begin field b2d43995-d729-4298-a0f1-7d7c4546e407 --><ul><li><strong>Assess for any new alarm symptoms</strong> that may suggest a <a class=\"topic-reference internal-reference\" href=\"/topics/dyspepsia-proven-gord/background-information/complications/\">complication</a> or other serious underlying pathology, and manage appropriately. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/gastrointestinal-tract-upper-cancers-recognition-referral/\">Gastrointestinal tract (upper) cancers - recognition and referral</a> for more information.</li><li><strong>For people with persistent or recurrent gastro-oesophageal reflux disease (GORD) symptoms despite </strong><a class=\"topic-reference internal-reference\" href=\"/topics/dyspepsia-proven-gord/management/dyspepsia-proven-gord/#initial-management\">initial&nbsp;management</a><strong>:</strong><ul><li>Consider whether an alternative diagnosis, such as cardiac or hepatobiliary disease, may be contributing to symptoms. See the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/chest-pain/\">Chest pain</a>, <a class=\"topic-reference external-reference\" href=\"/topics/angina/\">Angina</a>, <a class=\"topic-reference external-reference\" href=\"/topics/gallstones/\">Gallstones</a>, and <a class=\"topic-reference external-reference\" href=\"/topics/cholecystitis-acute/\">Cholecystitis - acute</a> for more information.</li><li>Check the person's adherence to initial management and reinforce <a class=\"topic-reference internal-reference\" href=\"/topics/dyspepsia-proven-gord/management/dyspepsia-proven-gord/#initial-management\">lifestyle advice</a>.</li></ul></li><li><strong>For people with persistent or recurrent symptoms and confirmed oesophagitis,</strong> consider one of the following options, depending on clinical judgement:<ul><li>Prescribe a further course of the initial full-dose proton pump inhibitor (PPI) for 1 month. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/dyspepsia-proven-gord/prescribing-information/proton-pump-inhibitors/\">Proton pump inhibitors</a> in <a class=\"topic-reference internal-reference\" href=\"/topics/dyspepsia-proven-gord/prescribing-information/\">Prescribing information</a> for more information.</li><li>Prescribe a double dose of the initial PPI for 1 month.</li><li>Add in a histamine (H<sub>2</sub>)-receptor antagonist (H<sub>2</sub>RA) at bedtime, such as ranitidine, particularly if there are nocturnal symptoms. Prescribe an H<sub>2</sub>RA for short-term use (for example for a 2-week course intermittently). See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/dyspepsia-proven-gord/prescribing-information/h2-receptor-antagonists/\">H2-receptor antagonists</a> in <a class=\"topic-reference internal-reference\" href=\"/topics/dyspepsia-proven-gord/prescribing-information/\">Prescribing information</a> for more information.</li></ul></li><li><strong>For people with persistent or recurrent symptoms and endoscopy-negative reflux disease,</strong> consider the following for 1 month:<ul><li>Switching to a H<sub>2</sub>RA, such as ranitidine.</li></ul></li><li><strong>For people with recurrent symptoms after initial management, consider the need for long-term treatment.</strong> Encourage the person to step down or stop treatment, if possible and appropriate (if there is no co-morbidity or co-medication that requires long-term PPI treatment):<ul><li>Use a PPI at the lowest effective dose to control symptoms.</li><li>Use a PPI as needed, if possible and appropriate.</li><li>Consider self-treatment with antacid and/or alginate therapy, although this is not recommended for long-term or continuous use.</li></ul></li><li><strong>If a person with severe oesophagitis has ongoing symptoms following </strong><a class=\"topic-reference internal-reference\" href=\"/topics/dyspepsia-proven-gord/management/dyspepsia-proven-gord/#initial-management\">initial&nbsp;management</a><strong>,</strong> consider one of the following options for 8 weeks, depending on clinical judgement:<ul><li>Prescribe a high dose of the initial PPI.</li><li>Switch to an alternative full-dose or high-dose PPI.</li><li>See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/dyspepsia-proven-gord/prescribing-information/proton-pump-inhibitors/\">Proton pump inhibitors</a> in <a class=\"topic-reference internal-reference\" href=\"/topics/dyspepsia-proven-gord/prescribing-information/\">Prescribing information</a> for more information.</li></ul></li><li><strong>If a person with severe oesphagitis has controlled symptoms, offer a full-dose PPI long-term as maintenance treatment.</strong> If there are ongoing or recurrent symptoms on treatment, consider whether to:<ul><li>Switch to an alternative full-dose or high-dose PPI, and/or</li><li>Seek specialist advice from a gastroenterologist.</li></ul></li><li><strong>Offer people on long-term treatment an annual review of their symptoms and treatment,</strong> and encourage the person to:<ul><li>Step down or stop treatment, if possible and appropriate, if there is no co-morbidity or co-medication that requires long-term full-dose PPI therapy, such as:<ul><li>Complicated or severe oesophagitis (including past dilatation of oesophageal stricture).</li><li>Barrett's oesophagitis. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/gastrointestinal-tract-upper-cancers-recognition-referral/\">Gastrointestinal tract (upper) cancers - recognition and referral</a>.</li><li>On long-term nonsteroidal anti-inflammatory drugs (NSAIDs) where a PPI is used for gastroprotection. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/nsaids-prescribing-issues/\">NSAIDs - prescribing issues</a>.</li><li>Previous bleeding peptic ulcer disease who remain <em>Helicobacter pylori </em>positive after at least two attempts at eradication. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/dyspepsia-proven-peptic-ulcer/\">Dyspepsia - proven peptic ulcer</a>.</li></ul></li></ul></li><li><strong>Consider arranging a referral to a gastroenterologist or upper gastrointestinal surgeon for </strong><a class=\"topic-reference internal-reference\" href=\"/topics/dyspepsia-proven-gord/management/dyspepsia-proven-gord/#specialist-investigations-management\">specialist investigations and management</a><strong>,</strong> if a person has proven GORD symptoms:<ul><li>That are refractory to treatment, persistent, or unexplained.</li><li>That are controlled on acid suppression therapy, but the person does not wish to continue treatment long-term.</li><li>That are responding to a PPI, but acid suppression therapy is not tolerated.</li><li>In association with <a class=\"topic-reference internal-reference\" href=\"/topics/dyspepsia-proven-gord/background-information/risk-factors/\">risk factors</a> for Barrett's oesophagus, for consideration of upper gastrointestinal endoscopy.</li></ul></li></ul><!-- end field b2d43995-d729-4298-a0f1-7d7c4546e407 --><!-- end item 4fc716bf-f9f8-4814-8227-cc0a3574baec -->","subChapters":[{"id":"fdd1adf3-4e2c-57bf-aaed-62ece6892ff6","slug":"specialist-investigations-management","fullItemName":"Specialist investigations and management","depth":4,"htmlHeader":"<!-- begin field 514d2b5c-1cc6-4f36-a846-a72e0160c849 --><h4>Specialist investigations and management</h4><!-- end field 514d2b5c-1cc6-4f36-a846-a72e0160c849 -->","summary":null,"htmlStringContent":"<!-- begin item 138d9ecf-906a-44bd-83c5-a72e0160c533 --><!-- begin field ae120e88-6071-4ea8-a643-a72e0160c849 --><h5>Specialist investigations</h5><ul><li>Oesophageal manometry and ambulatory 24-hour oesophageal pH monitoring (to quantify reflux and assess the relationship between reflux episodes and the person's symptoms).<ul><li>The latter investigation may help to exclude oesophageal motility disorders such as achalasia, and severe oesophageal hypomotility such as scleroderma-like oesophagus, before considering anti-reflux surgery.</li></ul></li><li>Barium swallow or meal (to help exclude structural disorders such as hiatus hernia or motility disorders such as achalasia).</li></ul><h5>Specialist management</h5><ul><li>Laparoscopic fundoplication is the gold standard for anti-reflux surgery, and involves mobilization of the fundus of the stomach which is then wrapped around the lower oesophagus.<ul><li>Surgery is associated with a small risk of mortality (about 1%) and complications such as gas-bloat syndrome, post-operative dysphagia, strictures, or recurrence of reflux symptoms.</li></ul></li><li>Other procedures that may be undertaken in specialist centres include:<ul><li>Endoscopic radiofrequency ablation.</li><li>Laparoscopic insertion of a magnetic bead band.</li><li>Endoscopic injection of bulking agents.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-gord/references/\">Bredenoord, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-gord/references/\">Katz et al, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-gord/references/\">NICE, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-gord/references/\">Anderson, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-gord/references/\">Maret-Ouda, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-gord/references/\">World Gastroenterology Organisation, 2015</a>]</p><!-- end field ae120e88-6071-4ea8-a643-a72e0160c849 --><!-- end item 138d9ecf-906a-44bd-83c5-a72e0160c533 -->","subChapters":[]},{"id":"a6626d16-4e56-512c-9414-9240521ded30","slug":"basis-for-recommendation-702","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 0681142a-65d9-4b49-9cb2-faf79513fb3c --><h4>Basis for recommendation</h4><!-- end field 0681142a-65d9-4b49-9cb2-faf79513fb3c -->","summary":null,"htmlStringContent":"<!-- begin item 702864cf-7cab-456f-9b9b-c0e15826e7d0 --><!-- begin field 7af9f45e-1f75-4127-a451-1288ab4dee2a --><p>The recommendations on the initial management of gastro-oesophageal reflux disease (GORD) are largely based on the National Institute for Health and Care Excellence (NICE) clinical guideline <em>Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-gord/references/\">NICE, 2014</a>], expert opinion in the World Gastroenterology Organisation (WGO) guideline <em>Global perspective on gastroesophageal reflux disease</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-gord/references/\">World Gastroenterology Organisation, 2015</a>], expert opinion in US <em>Guidelines for the diagnosis and management of gastroesophageal reflux disease</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-gord/references/\">Katz et al, 2013</a>], and expert opinion in review articles on GORD [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-gord/references/\">Bredenoord, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-gord/references/\">Anderson, 2015</a>].</p><h5>Assessing for any new alarm symptoms</h5><ul><li>The recommendation on assessing for any new alarm symptoms and managing appropriately is based on the NICE clinical guideline <em>Suspected cancer: recognition and referral</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-gord/references/\">NICE, 2015</a>].</li></ul><h5>Management of persistent or recurrent symptoms</h5><ul><li>The recommendations on management options for people with ongoing symptoms are based on variable-quality evidence cited by NICE regarding people with oesphagitis detected at endoscopy who do not respond to initial treatment with 1 month of full-dose proton pump inhibitor (PPI) therapy. Studies varied in sample size and defined population, and often had short-term follow-up of endoscopic-only outcomes [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-gord/references/\">NICE, 2014</a>]:<ul><li>There may be additional benefit in increasing the duration of initial PPI therapy from 4 to 8 weeks.</li><li>Doubling the dose of PPI may have a small effect in healing oesophagitis after 4 weeks.</li><li>There was no evidence that any PPI was more effective than another when compared at equivalent doses, and it is assumed that PPIs have a 'class effect'.</li><li>Adding a histamine (H<sub>2</sub>)-receptor antagonist (H<sub>2</sub>RA) at bedtime may improve symptoms in people who have nocturnal acid breakthrough in the short-term, however tachyphylaxis (rebound symptoms) may occur after 1 week, and ongoing H<sub>2</sub>RA therapy is likely to become increasingly ineffective.<ul><li>This is supported by expert opinion in a review article on GORD which states that the effect of additional suppression of nocturnal acid secretion may wear off within a few weeks [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-gord/references/\">Bredenoord, 2013</a>].</li><li>The recommendation to consider prescribing intermittent 2-week courses of an H<sub>2</sub>RA is based on the expert opinion of previous external reviewers of this CKS topic.</li></ul></li></ul></li><li>The recommendations on management options for people with endoscopy-negative reflux disease who have not responded to PPI therapy are based on the NICE clinical guideline, which states that individual people may respond to an H<sub>2</sub>RA, which is more effective than antacid therapy. NICE cites a systematic review comparing PPIs, H<sub>2</sub>RAs, and prokinetics in people with endoscopy-negative reflux disease, which found that [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-gord/references/\">NICE, 2014</a>]:<ul><li>PPIs were effective at preventing relapse of GORD symptoms when compared with placebo in 5 trials (n = 1167).</li><li>H<sub>2</sub>RAs were effective at preventing relapse of GORD symptoms when compared with placebo in 2 trials (n = 514).</li><li>Two head-to-head trials of PPI and H<sub>2</sub>RA therapy found a non-signficant trend favouring PPI therapy (n = 776).</li></ul></li><li>The recommendations on management options for people with severe oesophagitis with ongoing symptoms are based on the NICE guideline development group's clinical experience and expertise [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-gord/references/\">NICE, 2014</a>].</li></ul><h5>Stepping down or stopping treatment</h5><ul><li>The recommendation that PPIs should be used at the lowest effective dose for the shortest duration to reduce the risk of adverse effects associated with long-term PPI use is based on the NICE clinical guideline and expert opinion in a review article on GORD [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-gord/references/\">NICE, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-gord/references/\">Anderson, 2015</a>].</li><li>The NICE clinical guideline found good-quality evidence that intermittent PPI therapy is superior to placebo at controlling GORD symptoms, and recommends PPIs should be used as needed if possible, as a cost-effective option to promote patient self-management of their condition [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-gord/references/\">NICE, 2014</a>].</li><li>The NICE clinical guideline found limited evidence that antacid and/or alginate therapy is no more effective at healing oesophagitis than placebo, however NICE notes that it is often prescribed by primary healthcare professionals, and is often used as over-the-counter medication. It may provide short-term symptom relief, but does not prevent GORD symptoms [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-gord/references/\">NICE, 2014</a>].</li></ul><h5>Maintenance therapy for people with severe oesophagitis</h5><ul><li>The recommendation on the need for long-term PPI treatment for people with severe oesophagitis to prevent relapse is based on the NICE clinical guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-gord/references/\">NICE, 2014</a>].<ul><li>NICE found variable-quality evidence which contributed to a very low-quality network meta-analysis that found full-dose PPIs were more effective than low-dose PPIs, H<sub>2</sub>RAs, and placebo in preventing relapse for people with endoscopy-confirmed severe oesophagitis. The studies varied in sample size and defined population, and often had short-term follow-up of endoscopic-only outcomes. The meta-analysis was unable to determine which was the most cost-effective PPI to use and at what dose.</li></ul></li></ul><h5>Arranging specialist referral</h5><ul><li>The recommendations on referral are based on the NICE guideline development group's clinical experience and expertise [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-gord/references/\">NICE, 2014</a>], and are supported by expert opinion in the WGO guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-gord/references/\">World Gastroenterology Organisation, 2015</a>] and US guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-gord/references/\">Katz et al, 2013</a>].</li><li>The recommendation on considering referral if the person has risk factors for Barrett's oesophagus is based on evidence cited by NICE from 32 low-quality studies which identified a sub-group of people with GORD symptoms who may benefit from having an endoscopy to allow early identification of Barrett's oesophagus. These people may be at higher risk of developing oesophageal adenocarcinoma, and surveillance endoscopy may be indicated for people at higher risk of disease progression [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-gord/references/\">NICE, 2014</a>].</li></ul><p> </p><!-- end field 7af9f45e-1f75-4127-a451-1288ab4dee2a --><!-- end item 702864cf-7cab-456f-9b9b-c0e15826e7d0 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}